Hey, runn, look at ALVR. Looks like a real sweetheart. (Fido owns over 8%/Giliad too)
The filing spells it out. Its a couple million. Whether thats a waste or not, I have my opinion but these guys spend roughly 10 million a year. Some on licensing, a few employees salaries, and some on trials. It's hardly a get rich scheme. Of note the Cleveland Clinic had been paid 350k out of an estimated 2 million total for MS trial per 10q. With the holidays coming up, doesn't look like they will launch the trial before early next year. whether or not we get an update before then is getting less likely but you never know I guess. Likely some tax loss selling the next few weeks too.
We'll see how tight the ship is with their Israeli partnership. The ultimate masters of... *Poof*...
Cash reserves won't drop. You're really reaching now. People have been claiming that for years but they always run a tight ship
Yep and they're all in on it. Partnering up overseas to. Watch how the cash reserves drop. Charletons selling snake oil..
They didn't need to do this!!! Screwing shareholders over is NOT OKAY!!! This is THEFT!!!!
It's bold and shameless but certainly not criminal and happens every day. Convertible debt almost always ends up in the crapper for shareholders.
Which of course is why this is a crime! This is a publicly traded company on the NASDAQ exchange and the company is giving a huge and overt F-U to their common shareholders as they steal the assets of the company and transfer them to their private equity friends... It's such a bold and shameless move...
That's why this hasn't been an investment for a very long time.Thats why reverse split was always going to take place once top line results weren't positive. Even though they have the money to run additional trials, it still isn't an investment at this point
Think about how utterly INSANE this dilution is from the cash position of the company a few months ago before it began!!!! This is criminal!!!!
I haven't. I would be hesitant to say.
And Fidelity owns over eight percent of the shares outstanding.
Hey, runn, have you looked at ALVR? Seems like an incredible therapeutic, if it works?
Takes at least six months and appeals. I'm guessing they'll appeal with a reverse split plan
Same as the Petros deal. Insiders make a lot of money and shareholders are left empty handed.
Shouldn't Nasdaq have delisted them by now?
I just hope this acquisition is driven by science (Alkon and Tuchman) and good reason, versus another Private Equity scheme of the Silvermans.... Public companies should be accountable to their common shareholders but this company is accountable to the PE side that uses the public markets as an opportunity to steal...
I'm more interested in the mushroom compounds in regards to synaptic effects but not a lot of detail in that PR
Yeah, they have some compounds.
Not really sure what it means for us or how it plays out but the company did acquire a stake in an Israeli research lab or something similar today. Doesn't appear to be anything synergistic with Bryostatin but the diversification is probably the point...that and trying to see previous lenders get some of their money back in some fashion that is unlikely to benefit shareholders IMO.
Today's MIT letter (taken from Nature) excitatory cells having reelin/somatostatin in inhibitory neurons, hinder, don't help neuronal communication.
Yeah he has led a bunch of folks astray that hung on there all the way down and he'll lose folks here money too if they don't trade the bumps imo
Expect you refer to AVXL. Currently up 83%+ (Was up 850%+ when it shot up to $30 last year - back down to $6+ today but I expect it to return to highs + by end of year).
Nothing we don't already know but author did interview other experts in the field.
You might be down some on another AD table pounder he's pumped for awhile.
Nothing changes the fact this is heading for a reverse split and is years away from any type of AD approval Imo. We don't even know when the next AD trial will kick off or what they could potentially squander the cash on this go around as they look for "strategic alternatives". That's the current fear
It's complicated. I believe NTRP became PTPI with roughly a $20 million cash contribution that as I recall was the equivalent of $.80 per NTRP share (which became $4.00 after 1-5 split), then SNPX was treated as a dividend and the cost basis was something like $.25 or so, later adjusted after 1-5 to $1.25 and later adjusted again at 1-4 for $5.00...
The PTPI deal was mind numbingly stupid in terms of representing the interests of the common shareholders that wanted to invest in Bryostatin-1 and Alkon. The idea of "two shots on goal" was always just BS spin.
IMHO, our problem was then and still is that while many of us are good with investing in Bryostatin-1, the patents, licenses, and Alkon. The company's chairman and his PE buddies are more interesting in schemes for them to make money, and this is almost always at odds with the common shareholders interests... Alkon and Tuchman should get rid of Silverman and Weinstein and set a new course...
Not my strong point man. Wish I could be more helpful without reading through all the filings and PRs. GL
Very hard to trace info. I did find the final breakdown of the final merged entity (after some shenanigans), Neurotrope owners would increase to 49% of the combined company, leaving 51% to Petros shareholders. Subsequently spun out Synaptogenix. Price of stock with this and then reverse splits, etc… makes it very difficult to track.
I am thinking, I will split my original investment (total cost basis) that was in Neurotrope and conclude that post their merger and final spin out of the two public companies my original investment in Neurotrope would result in a cost model of 49% into Synaptogenix and 51% into Petros per their public announced agreement.
So after selling all my shares (post splits, if any, etc..) in Petros, this will give me my Petros proceeds. From this I can compute my loss by subtracting proceeds from my 51% of original investment in Neurotrope.
I think this is logical. What do you think?
Thanks. Will check.
I thought it was a 1 to 5 ratio for the Petros spinoff but you may want to check the 10k which should state it. My guess is if you had 1000 shares of Ntrp then you got 200 shares of petros which would be 20 shares after their split. Also the NTRP were split after that spinoff to gain Nasdaq but I don't remember what that split number was. 10k will tell. I'm just going on the fly
$ invested in Neurotrope, then initial
=> $% split into Petros and Synaptogenix?
My shares were part of the original block that were distributed by Neurotrope. Do you recall how the investment dollar (in total) split between the two new companies, Neurotrope and Petros Pharma? I vaguely recall it may have been 50/50? If I get this split ratio of my invested dollars, then current cost per share (post whatever further splits occurred) can be easily derived. Thanks.
Keep in mind the Petros spinoff shares which I believe were originally at a 5 for 1 share dividend, have also been split by a 10th I believe.
You probably need to call your broker and tell them about the splits and the Petros spinoff and hopefully they could more easily figure it out. I would be hesitent to take a guess. Depending on when you bought here there have been 2 separate splits and the spinoff.
Look.. it’s terrible what the fda has done to slow safe effective treatments
Basically y they and most of the medical community have become the Reepers best friends
It's interesting but they did do MRIs and the average time from initial diagnosis for this trial was over 3 years. I would like to see the patients screened from the diagnostic company you mentioned with the FDA approved diagnostic test that included PKCE monitoring.
I think they need a better screening of patients admitted in the “mild” group to insure the patients have AD vs. some other mild dementia. Could be why the placebo data for this group does not match expectations.
Didn’t they spin off a BRNI AD testing technique company that has a highly accurate quantitative skin based test vs. a subjective scoring method? Could provide more confidence.
Anyway, the treated patients retained good scores after the treatments stopped for the measurement period! Amazing.
Thanks for the link. Finally got to sit down at a desktop and read. Pages 5-7 are very in depth with individual patient scores plotted on the graphs. Separation at every data point and stat significant and growing from week 13 and beyond. Does lend some credence to the synaptic growth and maintenance MOA. Oddly enough one of the reasons the drug didn't prove stat significant over the more mild subgroup was once again due to the placebo group scoring a mean of +5 points. Definitely interesting data. I had previously had doubts as to whether an additional AD trial would be run, but it would be kind of hard to not run another one in a similar population after these results. Still the "n" is rather small and there are certainly questions lingering. That's the science. Now as an investment its currently trash and will likely be so until the inevitable reverse split or even longer IMO.
Agreed, it would be great to get more context...
I want to know if there is data that shows a 12 point decrease in SIB at this stage of dementia (or any stage of severe AD) could be expected over 10 months or what the company expectations were for the placebo. Maybe Doc will chime in with any thoughts at some point. I realize the numbers in this group are likely fairly small
That seems like powerful data to me! It's hard to reconcile a drug with this story and results, combined with cash and licenses with solid other key trial prospects, being priced on the capital market at almost zero, in fact, way below cash...
The peer review shows that the more severe patient placebo group declined over 12 points. I wonder how common that is in the AD population? We know that most of those patients were probably still taking other AD meds (other than memantine of course). It just seems like a big drop off and I'm trying to wrap my head around how memantine comes into play, if at all vs the odds that bryostatin stopped the decline cold for almost a year. Still thinking on this one.
Yes they have shares to sell for years as volume is just so bad routinely
It's great news! Of course, Josh Silverman and crew ALWAYS have enough shares to sell to throw cold water on any rally when needing a low price for their new shares... Great news so often has led to a negative share price result as they need to demoralize any potential rally...